Clinical Report: Brain MRI and FDG-PET in Neurodegenerative Disorder Diagnosis

Overview

Brain MRI and FDG-PET/CT are critical imaging modalities in diagnosing neurodegenerative diseases, particularly dementias such as Alzheimer's disease. MRI assesses structural changes including microvascular ischemic disease and patterns of brain atrophy, while FDG-PET provides metabolic information to differentiate dementing disorders.

Background

Neurodegenerative diseases, especially dementias like Alzheimer's disease, affect millions worldwide with increasing prevalence due to aging populations. Clinical evaluation includes laboratory tests, neurocognitive assessments, and brain imaging. Structural MRI is essential to exclude mimics and characterize atrophy patterns, while FDG-PET/CT aids in differential diagnosis by detecting regional brain metabolism abnormalities. These imaging tools complement each other to improve diagnostic accuracy and guide management.

Data Highlights

Key Findings

• White matter hyperintensities (WMH) on T2/FLAIR MRI correlate with cognitive decline and vascular risk factors; severity can be graded by the Fazekas scale.
• Patterns of sulcal and ventricular dilatation on MRI help identify normal pressure hydrocephalus (NPH) and disproportionately enlarged subarachnoid space hydrocephalus (DESH).
• 3D high-resolution T1-weighted MRI sequences enable quantitative volumetric brain analysis compared to age-matched controls.
• FDG-PET/CT after fasting and 18F-FDG administration reveals regional brain hypometabolism, aiding differential diagnosis among dementing disorders.
• 3D stereotactic surface projection (3D-SSP) statistical mapping enhances FDG-PET diagnostic accuracy by highlighting abnormal metabolic regions.
• Microhemorrhages and superficial siderosis on Gradient Echo or SWI MRI suggest cerebral amyloid angiopathy, an important consideration in dementia evaluation.

Clinical Implications

Incorporating brain MRI and FDG-PET/CT into the diagnostic workup of cognitive impairment improves identification of underlying neurodegenerative pathology and vascular contributions. MRI findings such as WMH burden and atrophy patterns guide differential diagnosis and management decisions. FDG-PET metabolic patterns further refine diagnosis, enabling tailored therapeutic strategies and prognostication.

Conclusion

Brain MRI and FDG-PET/CT are complementary imaging modalities essential for accurate diagnosis and management of neurodegenerative dementias. Their combined use enhances detection of structural and metabolic abnormalities, facilitating precise clinical decision-making.

References

1. Alzheimer's Association 2020 -- Dementia Statistics
2. Meta VCI Map Consortium -- WMH and Post-Stroke Cognitive Function
3. Fazekas et al. -- White Matter Hyperintensity Grading
4. 3D-SSP FDG-PET Imaging Studies -- Diagnostic Accuracy